STRO - Sutro Biopharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.95
+0.02 (+0.17%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close11.93
Open12.06
Bid11.94 x 800
Ask11.97 x 1200
Day's Range11.87 - 12.51
52 Week Range7.69 - 12.75
Volume148,257
Avg. Volume61,796
Market Cap275.928M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.88
Earnings DateFeb 05, 2020 - Feb 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.86
  • PR Newswire

    Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that the company will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 16, 2020, at 9:00 AM PST at the Westin St. Francis in San Francisco.

  • PR Newswire

    Sutro Biopharma Appoints James Panek to Board of Directors

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the appointment of James P. Panek to its Board of Directors. Mr. Panek brings more than 40 years of experience in the biotech and pharmaceutical industry.

  • Do Hedge Funds Love Sutro Biopharma, Inc. (STRO)?
    Insider Monkey

    Do Hedge Funds Love Sutro Biopharma, Inc. (STRO)?

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • PR Newswire

    Sutro Biopharma to Present at the Stifel 2019 Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 19, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview and business update at the Stifel 2019 Healthcare Conference on Wednesday, Nov. 20, 2019, at 9:10 a.m. EST at the Lotte New York Palace hotel in New York City. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.

  • Sutro Biopharma, Inc. (STRO): Hedge Funds Are Snapping Up
    Insider Monkey

    Sutro Biopharma, Inc. (STRO): Hedge Funds Are Snapping Up

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]

  • PR Newswire

    Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments

    STRO-002 Initial Safety Data from an Ongoing Phase 1 Trial in Ovarian and Endometrial Cancers presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 29, 2019 STRO-001 ...

  • Introducing Sutro Biopharma (NASDAQ:STRO), The Stock That Dropped 15% In The Last Year
    Simply Wall St.

    Introducing Sutro Biopharma (NASDAQ:STRO), The Stock That Dropped 15% In The Last Year

    Sutro Biopharma, Inc. (NASDAQ:STRO) shareholders should be happy to see the share price up 11% in the last month. But...

  • Benzinga

    The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 28.) AstraZeneca plc (NYSE: AZN ) ( reported positive ...

  • PR Newswire

    Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer

    - Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston - STRO-002 was well tolerated in patients with advanced relapsed and refractory ...

  • Benzinga

    The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

    Earnings, clinical trial readouts and positive FDA verdicts catalyzed fairly robust performances by biotech stocks last week. Biogen Inc  (NASDAQ: BIIB )'s  about-face with respect to its Alzheimer's drug ...

  • PR Newswire

    Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

    SOUTH SAN FRANCISCO, Calif. , Oct. 16, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming AACR-NCI-EORTC International Conference on ...

  • PR Newswire

    Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

    SOUTH SAN FRANCISCO, Calif., Oct. 8, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that it has achieved a milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany and is entitled to receive a milestone payment.  The milestone was achieved upon the designation by Merck KGaA, Darmstadt, Germany of an undisclosed bispecific antibody drug conjugate (ADC) as a clinical development candidate with approval to advance to IND-enabling studies. This candidate was discovered using Sutro's XpressCF+™ drug discovery and manufacturing technology and includes a proprietary linker-warhead also discovered by Sutro.

  • PR Newswire

    Sutro Biopharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 4, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, Sept. 10, 2019, at 11:40 AM EDT, in New York City. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.

  • PR Newswire

    Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments

    STRO-001 Initial Safety Data from an Ongoing Phase 1 Trial in Myeloma and Lymphoma presented at the European Hematology Association ("EHA") Congress, June 15, 2019 STRO-002 Phase 1 Clinical Trial ...

  • PR Newswire

    Sutro Biopharma to Present at the 2019 Wedbush PacGrow Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 8, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that its Chief Business Officer, Stephen Worsley, will present at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 13 at 1:20 p.m. EDT in New York City. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.

  • Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
    Simply Wall St.

    Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Here’s What Hedge Funds Think About Sutro Biopharma, Inc. (STRO)
    Insider Monkey

    Here’s What Hedge Funds Think About Sutro Biopharma, Inc. (STRO)

    Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]

  • PR Newswire

    Sutro Biopharma Appoints Biopharma Veteran Connie Matsui as Board Chair

    SOUTH SAN FRANCISCO, Calif., June 24, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that Connie Matsui, retired Executive Vice President of Biogen Idec, has been appointed as Chair of Sutro's Board of Directors. In joining the Sutro Board, Ms. Matsui brings more than 35 years of innovative and principled leadership spanning the banking, biotechnology and nonprofit sectors.

  • PR Newswire

    Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

    SOUTH SAN FRANCISCO, Calif., June 18, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that Steve Worsley, Chief Business Officer, will present a company overview at the JMP Securities Life Sciences Conference on Thursday, June 20 at 12:30 p.m. ET at the St. Regis Hotel in New York. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.

  • PR Newswire

    Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress

    SOUTH SAN FRANCISCO, Calif., June 15, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced encouraging interim safety data from an ongoing Phase 1 dose escalation clinical trial of its product candidate STRO-001, a novel, specific and homogeneous anti-CD74 antibody-drug conjugate (ADC), as a potential therapy for patients with B-cell malignancies. The interim data from the trial includes 21 patients and separate dosing cohorts for multiple myeloma (10 MM patients) and non-Hodgkin lymphoma (11 NHL patients), was presented at the 24th European Hematology Association (EHA) Congress in Amsterdam.

  • PR Newswire

    Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress

    SOUTH SAN FRANCISCO, Calif., May 16, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that the company will present at the upcoming European Hematology Association (EHA) Congress being held June 13-16, 2019, in Amsterdam. The abstract summarizes preliminary results from the first 14 patients enrolled in the company's ongoing Phase 1 study of STRO-001, the first antibody-drug conjugate generated with Sutro's novel cell-free protein synthesis technology, in patients with advanced B-cell malignancies.

  • PR Newswire

    Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments

    STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data to be presented at the European Hematology Association ("EHA") Congress, June 15, 2019 STRO-002 Phase 1 Clinical ...

  • PR Newswire

    Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., April 4, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9 at 4:50 p.m. ET at the Westin Grand Central Hotel in New York. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.